Contract logistics provider DHL Supply Chain has opened an 8,200 sq m Pharma Hub in Singapore.
Strategically located near Tuas Bio-Medical Park, the Pharma Hub offers seamless connectivity to Changi Airport and Tuas Mega Port, enabling efficient regional and global distribution of pharmaceutical shipments.
The €10m facility is part of DHL Group’s €500m investment into its Life Science and Healthcare (LSHC) infrastructure in Asia Pacific, under the group’s Strategy 2030. This strategy is behind the new DHL Health Logistics brand and a €2bn investment into the group’s logistics
capabilities in the life sciences and healthcare sector over the next five years.
DHL Supply Chain Asia Pacific chief executive Javier Bilbao said: “At DHL Supply Chain, we are committed to supporting the rapidly growing LSHC sector in Asia Pacific where there is a growing demand for transformative healthcare solutions due to longer lifespans, personalised treatments and rising consumer expectations.
“By 2030, the region’s medical market is projected to reach USD138 billion (approximately €127bn), reflecting the critical need for resilient and efficient supply chains. As part of DHL Group’s Strategy 2030, we have invested ahead to strengthen our infrastructure and capabilities, ensuring we can meet the evolving and increasingly complex needs of our customers.”
Eunis Hew, DHL Supply Chain Singapore managing director, said Singapore is “laser-focused” on becoming a global leader in life sciences and medtech innovation.
She went on: “With the new Pharma Hub in Jurong, we have over 36,000 sq m of warehouse space in Singapore dedicated to LSHC operations. Our current operations include being the regional distribution centres for multiple medical device multinationals, clinical trials support and other value-added services.”
Other forthcoming LHSC investments include sites in South Korea and one in Bhiwani, India.
